SCHEMBL22650873

SCHEMBL22650873

Cc1ccc(S(=O)(=O)NCCc2nc3ccccc3[nH]2)cc1

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.77
GAA P10253 2/20 0.77
LMNA P02545 3/20 0.55
TP53 P04637 1/20 0.55
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
HSD17B10 Q99714 1/20 0.55
HTT P42858 1/20 0.54
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 2/20 0.52
MEN1 O00255 1/20 0.52
NTRK1 P04629 1/20 0.52
XDH P47989 1/20 0.52
CYP19A1 P11511 1/20 0.51
HMOX1 P09601 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22633565 0.90 GAA (0.61) SMN1; SMN2GAALMNAHSD17B10HTT
SCHEMBL28518354 0.88 SMN1; SMN2 (0.67) SMN1; SMN2GAALMNATP53CASP1
SCHEMBL13405875 0.88 GAA (0.67) SMN1; SMN2GAALMNATP53HSD17B10
SCHEMBL12768582 0.87 SMN1; SMN2 (1.00) SMN1; SMN2GAALMNATP53HSD17B10
SCHEMBL23649505 0.83 KCNA5 (0.60) SMN1; SMN2GAALMNAKMT2AALDH1A1
SCHEMBL3537167 0.82 LMNA (0.54) SMN1; SMN2GAALMNATP53HSD17B10
SCHEMBL23648910 0.80 MAPT (0.53) SMN1; SMN2GAALMNAHTTKMT2A
SCHEMBL23649382 0.78 KCNA5 (0.57) SMN1; SMN2GAALMNAKMT2AALDH1A1
SCHEMBL6366763 0.78 SMN1; SMN2 (0.66) SMN1; SMN2GAALMNATP53HSD17B10
SCHEMBL13406150 0.78 SMN1; SMN2 (0.52) SMN1; SMN2GAALMNAHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200354327-A1 COMPOUND HAVING STAT3 INHIBITORY ACTIVITY AND USE THEREOF CYTUS H&B CO LTD (KR) 2020-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200354327-A1 COMPOUND HAVING STAT3 INHIBITORY ACTIVITY AND USE THEREOF STAT3, JAK2, STAT6 SMN1; SMN2 4484/4885GAA 2101/4885LMNA 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.